Tessera Therapeutics News and Activities

Presence

Tessera Therapeutics develops gene writing medicines for genetic diseases and cancer. Its products and research services support patients, healthcare providers, and biopharmaceutical partners.

Tessera Therapeutics products and services overview:

Gene editing
Cell therapies
Cancer therapies
Research services

Revenue: ~$0 million

Employees: 230

Headquarters: Cambridge, United States (USA)

Tessera Therapeutics is one of the...

Acquisition, funding and merger involving Tessera Therapeutics.

Tessera Therapeutics has just announced a $150 Million fundraising (posted on December 1 2025).

Executives

View the org chart displaying its 24 main executives

Most searched biographies at Tessera Therapeutics

Popular executive movements at Tessera Therapeutics

Anne-Virginie Eggimann, Chief Regulatory Officer, has left the company (posted on March 10 2026).
Howard Liang who was President and Chief Financial Officer, becomes President (posted on December 10 2025).
Kathy Bergsteinsson has joined the company as Chief Financial Officer (posted on December 10 2025).

Click here to view some more movements at Tessera Therapeutics

Create your alert
to follow the executive moves at Tessera Therapeutics.